Kuwait Pharmaceuticals and Healthcare Report Q3 2009
Published By: Business Monitor International
June 2009
R302-6600
Online Download $495.00
Description
Kuwait’s pharmaceutical market is small in regional terms. Combined sales of over-the-counter (OTC)and prescription drugs reached a total of US$377mn in 2008, and we expect this to reach US$462mn by2013 - representing a compound annual growth rate (CAGR) of 4.17% in US dollar terms.Pharmaceutical spending will account for 0.27% of GDP, with per capita expenditure at US$136 by theend of the forecast period. We expect growth to be driven by the strong bias toward patented drugs, whichstill dominate the market.
With little or no enforced incentives for prescribers or dispensers to substitute for generics wherepossible, this looks likely to continue in the medium term. However, we note that import policies in theregion have all been affected by unfavourable currency fluctuations against the euro when procuring EUmedicines. We note that the Kuwaiti government is not actively encouraging a domestic manufacturingindustry, which restricts choices on imports and in addition means the country is heavily reliant on thosemedicines.
BMI’s Burden of Disease Database (BoDD) reveals that the number of disability-adjusted life years(DALYs) lost to communicable diseases in Kuwait will decrease from 29,836 in 2008 to 24,888 by 2030.Meanwhile, the DALYs lost to non-communicable disease will rise from 190,740 in 2008 to 258,306 by2030. The main driver for this growth is attributed to the rise in obesity and obesity-related disordersincluding hypertension, diabetes, and cardiovascular disease.
We note that chronic conditions pose a significant burden on healthcare services and directly lead to a risein prescription medication spending. This makes the patented drug market in these therapeutic areasparticularly attractive to multinational drugmakers looking for new export destinations in the Middle East.Generic drugs are slowly gaining market share, though government policy on substitution needs to bedrafted and implemented to encourage further growth in this sector.
|
Table of Contents
- Executive Summary
- SWOT Analysis
- Kuwait Pharmaceuticals And Healthcare Industry SWOT
- Kuwait Political SWOT
- Kuwait Economic SWOT
- Kuwait Business Environment SWOT
- Pharmaceutical Business Environment Ratings
- Table: Regional Business Environment Ratings, Q309
- Limits Of Potential Returns
- Risks To Realisation Of Returns
- Kuwait - Market Summary
- Regulatory Regime
- Foreign Direct Investment Regulations
- Intellectual Property Regime
- IP Shortcomings
- Pricing And Reimbursement Regime
- Public Procurement Of Medicines
- Regional Harmonisation
- Free Trade Agreements
- Industry Developments
- Epidemiology
- Healthcare Sector
- Primary Care
- Secondary Care
- Recent Public Health Developments
- Healthcare Insurance
- Healthcare Reforms
- Regional Developments
- International Collaboration
- Pharmaceutical Sector
- Research And Development
- Biotechnology Sector
- Medical Devices
- Table: Diverse Potential For Product Launches: New Products For 2009
- Industry Forecast Scenario
- Overall Market Forecasts
- Table: Kuwait - Drug Expenditure Indicators,
- Key Growth Factors - Industry
- Table: Kuwait - Health Expenditure Indicators
- Key Growth Factors - Macroeconomic
- Table: Kuwait - Economic Activity, 2006-2013
- Prescription Drug Market Forecast
- Table: Kuwait - Prescription Market Indicators, Historical Data And Forecasts (KWDmn unless otherwise stated)
- Patented Drug Market Forecast
- Table: Kuwait - Patented Market Indicators
- Generic Drug Market Forecast
- Table: Kuwait - Generics Market Indicators, Historical Data And Forecasts
- OTC Drug Market Forecast
- Table: Kuwait - OTC Market Indicators, Historical Data And Forecasts (KWDmn unless otherwise stated)
- Export/Import Drug Market Forecasts
- Table: Kuwait - Pharmaceutical Trade Indicators, Historical Data And Forecasts (US$mn unless otherwise stated)
- Medical Devices Forecast
- Table: Kuwait’s Medical Devices Market, 2003-2013
- Other Healthcare Data
- Table: Kuwait - Other Healthcare Indicators, Historical Data And Forecasts, 2003-2013
- Key Risks To BMI Forecasts
- Competitive Landscape
- Company Profiles
- Multinationals
- Novartis
- Sanofi-Aventis
- Pfizer
- GlaxoSmithKline
- Merck & Co
- Johnson & Johnson
- Indigenous Players
- Advanced Technology Company
- Bader Sultan & Bros
- Safwan Trading And Contracting Company
- Country Snapshot: Kuwait Demographic Data
- Section 1: Population
- Table: Demographic Indicators, 2005-2030
- Table: Rural/Urban Breakdown, 2005-2030
- Section 2: Education And Healthcare
- Table: Education, 2002-2005
- Table: Vital Statistics, 2005-2030
- Section 3: Labour Market And Spending Power
- Table: Employment Indicators, 1997-2006
- Table: Consumer Expenditure, 2000-2012
- BMI Forecast Modelling
- How We Generate Our Pharmaceutical Industry Forecasts
- Pharmaceutical Business Environment Ratings Methodology
- Ratings Overview
- Table: Pharmaceutical Business Environment Indicators
- Weighting
- Table: Weighting Of Components
- Sources
|
Order Form * Please reference product number R302-6600 when ordering or inquiring.
MindBranch, Inc.,
131 Ashland St., Suite 200 North Adams, MA 01247
tel: 800-774-4410
fax: +1-413-664-9791
www.mindbranch.com
|
